| Luke T Mallory, DPT | |
|
16658 N Highway 41, Rathdrum, ID 83858-6890 | |
| (208) 687-9195 | |
| (208) 687-9750 |
| Full Name | Luke T Mallory |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine & Rehabilitation |
| Location | 16658 N Highway 41, Rathdrum, Idaho |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417712589 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | PT-8974 (Idaho) | Primary |
| Entity Name | Lakeland Physical Therapy And Sports Injuries P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083896674 PECOS PAC ID: 9537158787 Enrollment ID: O20040511001525 |
News Archive
A study of more than 75,000 adults found that taking supplemental multivitamins, vitamin C and E and folate do not decrease the risk of lung cancer.
Micell Technologies,™ Inc. today announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries) clinical trial. Stefan Verheye, M.D., Ph.D. at Middelheim Hospital, Antwerp, Belgium enrolled the first patient in the study. This clinical investigation is being conducted to support CE Mark approval of the company's MiStent™ Drug-Eluting Coronary Stent System (MiStent DES).
Cold feet-those chilly appendages that plague many people in the winter and an unlucky few all year round-can be the bane of existence for singles and couples alike. In a new study, scientists led by Selvi C. Jeyaraj of the Research Institute at Nationwide Children's Hospital have identified a biological mechanism that may be responsible for icy extremities: an interaction between a series of molecules and receptors on smooth muscle cells that line the skin's tiny blood vessels.
Almost 8 percent of patients experience loss of at least one implant within ten years. Even more develop peri-implantitis. Patients with periodontitis run a greater risk of both implant loss and peri-implantitis. A doctoral thesis at Sahlgrenska Academy has explored the various issues.
The worldwide first clinical trial for the development of a Parkinson´s vaccine has now been started by AFFiRiS AG.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Luke T Mallory, DPT 16658 N Highway 41, Rathdrum, ID 83858-6890 Ph: (208) 687-9195 | Luke T Mallory, DPT 16658 N Highway 41, Rathdrum, ID 83858-6890 Ph: (208) 687-9195 |
News Archive
A study of more than 75,000 adults found that taking supplemental multivitamins, vitamin C and E and folate do not decrease the risk of lung cancer.
Micell Technologies,™ Inc. today announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries) clinical trial. Stefan Verheye, M.D., Ph.D. at Middelheim Hospital, Antwerp, Belgium enrolled the first patient in the study. This clinical investigation is being conducted to support CE Mark approval of the company's MiStent™ Drug-Eluting Coronary Stent System (MiStent DES).
Cold feet-those chilly appendages that plague many people in the winter and an unlucky few all year round-can be the bane of existence for singles and couples alike. In a new study, scientists led by Selvi C. Jeyaraj of the Research Institute at Nationwide Children's Hospital have identified a biological mechanism that may be responsible for icy extremities: an interaction between a series of molecules and receptors on smooth muscle cells that line the skin's tiny blood vessels.
Almost 8 percent of patients experience loss of at least one implant within ten years. Even more develop peri-implantitis. Patients with periodontitis run a greater risk of both implant loss and peri-implantitis. A doctoral thesis at Sahlgrenska Academy has explored the various issues.
The worldwide first clinical trial for the development of a Parkinson´s vaccine has now been started by AFFiRiS AG.
› Verified 9 days ago